Business Context and Reporting Period
Company: Medtronic Public Limited Company (Medtronic Plc)
Filing Type: Form 8-K (Current Report)
Date of Report: December 12, 2018
Event: Entry into a Material Definitive Agreement (Amended and Restated Credit Agreement)
Key Financial Metrics
This filing details a new credit facility rather than reporting operational financial performance metrics such as revenue, profit, or cash flow.
- Facility Size: $3.5 billion unsecured revolving credit facility.
- Term: Five years, subject to two one-year extension options.
- Interest Rates (Variable):
- LIBO Rate plus a margin of 0.500% to 1.125% (based on long-term debt ratings).
- Alternate Base Rate plus a margin of 0.000% to 0.125% (based on long-term debt ratings).
- Commitment Fee: 0.045% to 0.110% per annum on unused commitments (ratings-based).
- Guarantors: Medtronic plc (Parent) and Medtronic, Inc.
Material Changes Versus Prior Period
The new Credit Agreement replaces the previous Amended and Restated Credit Agreement dated November 7, 2014 (effective January 26, 2015). Under the prior agreement, the Company and Medtronic were co-borrowers. The new structure designates Medtronic Global Holdings S.C.A. as the primary borrower with certain subsidiaries as designated borrowers, while Parent and Medtronic, Inc. serve as guarantors.
Guidance, Outlook, and Management Commentary
Intended Use: The commitments are intended for general corporate purposes, specifically to backstop the Company's $3.5 billion commercial paper program.
Features: The agreement includes a multicurrency borrowing feature for specified foreign currencies and contains customary representations, warranties, conditions precedent, events of default, and affirmative and negative covenants.
Outlook: No specific financial guidance or outlook regarding future earnings or revenue was provided in this filing.
Important Facts for Investor Verification
- Verify the Company's current long-term debt ratings to determine the specific applicable interest rate margins and commitment fees.
- Confirm the status of the $3.5 billion commercial paper program to understand the utilization of this backstop facility.
- Review the full text of the Credit Agreement (Exhibit 10.01) for specific affirmative and negative covenants that may restrict future corporate actions.
- Note that the filing does not provide data on revenue, net income, operating cash flow, or total debt levels outside of this specific facility.